The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies

Breast

Volumn 16, Issue 1, 2007, Pages 104-107

  Siziopikou, Kalliopi P ^a   Cobleigh, Melody ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Basal subtype of breast carcinomas; Breast cancer; EGFR; HER2; Targeted therapies

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR MECHANICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 33846587923     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2006.09.003     Document Type: Article

References (26)

1. Perou C.M., Sorlie T., van Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
2. van't Veer L.J., Dai H., and van de Vijver M.J. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
3. Sorlie T., Perou C.M., Tibshinari R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98 (2001) 10869-10874
4. Rouzier R., Perou C., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 (2005) 5678-5685
5. Abd El-Rehim D.M., Pinder S.E., Paish C.E., Bell J., Blamey R.W., Robertson J.F., et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203 (2004) 661-671
6. Livasy C.A., Karaca G., Nanda R., Tretiakova M.S., Olopade O.I., Moore D.T., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19 (2006) 264-271
7. Matos I., Dufloth R., Alvarenga M., Zeferino L.C., and Schmitt F. p63, cytokeratin 5 and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 447 (2005) 688-694
8. Bradley B.B., Schnitt S.J., and Collins L.C. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 19 (2006) 617-621
9. Siziopikou K.P., Ariga R., Proussaloglou K.E., Forbes D., Valadez C., and Gattuso P. Cobleigh: the challenging ER-negative/PR-negative/HER2-negative patient; a promising candidate for EGFR targeted therapy?. Breast Cancer Res Treat 88 (2004) S24
10. Green M.R. Targeting targeted therapy. N Engl J Med 350 (2004) 2191-2193
11. Pao W., and Miller V.A. Epidermal growth factor receptor mutations, small molecule kinase inhibitors and non-small cell lung cancer: current knowledge and future directions. J Clin Oncol 23 (2005) 2556-2568
12. Herbst R.S., and Bunn P.A. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 9 (2003) 5813-5824
13. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 353 (2005) 172-187
14. Slamon D.J., Leyland-Jones B., Shak S., Fucks H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
15. Herceptin combined with chemotherapy improves disease-free survival for patients with early breast cancer. Bethesda, MD: National Cancer Institute; April 25, 2005. (at 〈http://www.nci.nih.gov/newscenter/pressreleases/〉).
16. Averbuch S., Kcenler M., Morris C., and Wakeling A. Therapeutic potential of tyrosine kinase inhibitors in breast cancer. Cancer Invest 21 (2003) 782-791
17. Spector N.L., Xia W., Burris H., Hurwitz H., Dees E.C., Dowlati A., et al. Study of the biologic effects of lapatininb, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kniases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23 (2005) 2502-2512
18. Mass R.D. The HER receptor family: a rich target for therapeutic development. Int J Radiat Oncol Biol Phys 58 (2004) 932-940
19. Sartor C.I., Zhou H., Perou C.M., and Ethier S.P. Basal-like breast tumor-derived cell lines are growth inhibited and radiosensitized by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Breast Cancer Res Treat 88 Suppl S34 (2004)
20. Lu C., Speers C., Zhang Y., Xu X., Hill J., Steinbis E., et al. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 95 (2003) 1825-1833
21. Cunliffe H.E., Ringner M., Bilke S., Walker R.L., Cheung J.M., Chen Y., et al. The gene expression response of breast cancer to growth regulators: patterns and correlation with tumor expression profiles. Cancer Res 63 (2003) 7158-7166
22. Collett K., Stefansson I.M., Eide J., Braaten A., Wang H., Eide G.E., et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 14 (2005) 1108-1112
23. Jones C., Ford E., Gillett C., Ryder K., Merrett S., Reis-Filho J.S., et al. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res 10 (2004) 5988-5997
24. Foulkes W.D., Stefansson I.M., Chappuis P.O., Begin L.R., Goffin J.R., Wong N., et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95 (2003) 1482-1485
25. Lakhani S.R., Reis-Filho J.S., Fulford L., Penault-Llorca F., van der Vijver M., Parry S., et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11 (2005) 5175-5180
26. Palacios J., Honrado E., Osorio A., Cazorla A., Sarrio D., Barroso A., et al. Phenotypic characterization of BRCA1 and BRCA2 tumors based on a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 90 (2005) 5-14